41 completed, 10 terminated, 7 unknown, 6 not yet recruiting. 27 Phase 2, 17 Phase 3, 13 Phase 1, 11 Not applicable.
Follow Metastases: new trials by email Literature Review of Metastases trials Research Report on Metastases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| High Dose Radiotherapy for Palliation (Hi-D) Palliative Radiotherapy - Metastases, Palliative Radiotherapy | Not applicable | Not yet recruiting | British Columbia Cancer Agency | 21 | 2027-03-01 | 2026-08-12 |
| Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases. LATTICE Radiotherapy, Standard radiotherapy - Metastases, Metastatic Cancer | Phase 2 | Recruiting | Stanford University | 80 | 2026-08-28 | 2026-09-09 |
| Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors NCP-CD47 siRNA intratumorally injection - Solid Tumor Cancer, Metastases | Phase 1 | Not yet recruiting | West China Hospital | 9 | 2026-05-30 | 2026-05-13 |
| Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer Sintilimab, Lenvatinib, Comprehensive Local Consolidative Therapy - Hepatocellular Carcinoma (HCC), Metastases | Phase 3 | Not yet recruiting | Tongji Hospital | 400 | 2026-05-30 | 2026-04-17 |
| Exercise Training in Women With Metastatic Breast Cancer Exercise - Cancer, Metastases | Not applicable | Not yet recruiting | State University of Londrina | 78 | 2026-04-01 | 2026-04-13 |
| Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients Zanidatamab, Pembrolizumab, mFOLFOX - Gastroesophageal Adenocarcinoma, First Line Therapy | Phase 2 | Recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 80 | 2026-01-16 | 2026-06-30 |
| Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC Sacituzumab tirumotecan, Anlotinib - NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC Stage IIIB~IV | Phase 2 | Active not recruiting | Nanfang Hospital, Southern Medical University | 38 | 2025-08-13 | 2026-07-14 |
| SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors SABR - Breast Cancer, Metastases | Not applicable | Not yet recruiting | British Columbia Cancer Agency | 40 | 2025-07-01 | 2025-04-24 |
| EpCAM-Targeted Surface-Enhanced Raman Spectroscopy Nanotags for Rapid Evaluation of Surgical Margins and Sentinel Lymph Node Metastasis Status in Breast Cancers SERS detection - Sentinel Lymph Node, Breast Cancers | Not yet recruiting | Yunnan Cancer Hospital | 40 | 2025-06-15 | 2025-06-12 | |
| Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status NIR-II Probe(i.e ICG-POL6326) incubation solution - Breast Cancer, Sentinel Lymph Node | Recruiting | Yunnan Cancer Hospital | 40 | 2024-09-01 | 2024-12-03 | |
| Longitudinal Study of Local Ablative Therapy in Oligometastatic Disease Local ablative therapy (LAT) - Oligometastatic Disease, Metastases | Not applicable | Recruiting | Gitte Fredberg Persson MD PhD | 1200 | 2024-04-15 | 2024-04-16 |
| Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases Yttrium-90 (Y-90) resin microspheres - Metastases | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 50 | 2022-11-16 | 2026-05-26 |
| Liver Transplantation for Unresectable GIST Liver Metastases Liver Transplantation - Liver Diseases, Liver Cancer | Not applicable | Unknown | Hospital Universitario Virgen de la Arrixaca | 50 | 2022-05-01 | 2022-03-11 |
| Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC) Sintilimab, SBRT, Platinum based chemotherapy - Head and Neck Squamous Cell Carcinoma, Metastases | Phase 2 | Unknown | Jun-Lin Yi, MD | 50 | 2021-12-01 | 2021-11-29 |
| 68Ga-PSMA PET in the Renal Cell Carcinoma PSMA PET - Renal Cancer, Metastases | Not applicable | Recruiting | Xijing Hospital | 300 | 2021-06-01 | 2026-03-11 |
| 68Ga-PSMA PET in the Prostate Cancer PSMA PET - Prostatic Neoplasms, Metastases | Not applicable | Unknown | Xijing Hospital | 300 | 2021-06-01 | 2024-01-25 |
| Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment system treatment and surgery, system treatment - Neuroendocrine Tumors, Metastases | Unknown | Fudan University | 180 | 2019-08-25 | 2019-09-24 | |
| CE-IOUS Impact on Surgical Strategy of Liver Tumours and Liver Metastases CE-IOUS - Liver Neoplasms, Liver/Hepatobiliary Cancer | Completed | University of Regensburg | 500 | 2017-01-01 | 2022-03-17 | |
| Whole-body MRI for the Detection of Metastasis Breast Cancer, Metastases | Withdrawn | Norwegian University of Science and Technology | 2016-03-01 | 2016-08-10 | ||
| Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER) Buparlisib - Malignant Melanoma, Metastases | Phase 2 | Unknown | University Hospital Tuebingen | 22 | 2015-07-01 | 2017-05-03 |
Showing 20 of 75. Sign in to see all of them.
Neoplasm Metastasis (75) · Neoplasms (18) · Breast Neoplasms (16) · Colorectal Neoplasms (13) · Carcinoma (5) · Carcinoma, Hepatocellular (5) · Melanoma (5) · Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Renal Cell (3) · Liver Neoplasms (3) · Lung Neoplasms (3) · Prostatic Neoplasms (3) · Brain Neoplasms (2) · Cholangiocarcinoma (2) · Colonic Neoplasms (2)
Neoplastic Processes (75) · Pathologic Processes (75) · Pathological Conditions, Signs and Symptoms (75) · Neoplasms by Site (58) · Neoplasms (57) · Digestive System Diseases (22) · Digestive System Neoplasms (22) · Neoplasms by Histologic Type (22) · Skin Diseases (22) · Skin and Connective Tissue Diseases (22) · Breast Diseases (16) · Gastrointestinal Diseases (16) · Gastrointestinal Neoplasms (15) · Neoplasms, Glandular and Epithelial (14) · Colonic Diseases (13)
Bevacizumab (5) · Capecitabine (5) · Panitumumab (3) · trebananib (3) · Cetuximab (2) · Fluorouracil (2) · IFL protocol (2) · Leucovorin (2) · Oxaliplatin (2) · Radiosurgery (2) · Surgical Procedures, Operative (2) · ixabepilone (2) · pembrolizumab (2) · sintilimab (2) · volociximab (2)
Amgen (7) · Bristol-Myers Squibb (3) · Genentech, Inc. (3) · Sanofi (3) · Biogen (2) · British Columbia Cancer Agency (2) · Celgene (2) · Eli Lilly and Company (2) · R-Pharm (2) · Washington University School of Medicine (2) · Xijing Hospital (2) · Yunnan Cancer Hospital (2) · Abbott (1) · AstraZeneca (1) · Barretos Cancer Hospital (1)
United States (30) · Canada (12) · France (12) · Germany (11) · China (9) · Brazil (8) · Spain (8) · United Kingdom (8) · Argentina (7) · Belgium (6) · Hungary (6) · Italy (6) · Australia (5) · South Korea (5) · Austria (4)
Andres Forero, M.D. (2) · Agop Y. Bedikian, MD (1) · Alexander Stein, Prof. Dr. (1) · Antoine Italiano, MD/PhD (1) · Antoni Ribas, MD (1) · Beathe Sitter, PhD (1) · Catherine Van Poznak, MD (1) · Ching-Wei Tzeng, MD (1) · Colin P. Curran, M.D. (1) · Cordula Petersen, Prof. (1) · Cornelis JA Punt, Prof MD PhD (1) · David Linehan, M.D. (1)
PMID 30679026, PMID 31378656, PMID 34213592, PMID 36606664, PMID 17876014, PMID 17968020, PMID 18316791, PMID 20525992, PMID 21128114, PMID 21937232, PMID 22067397, PMID 22694829, PMID 23361051, PMID 23400564, PMID 23444228, PMID 23625191, PMID 23653243, PMID 23942774, PMID 24472478, PMID 25214238, PMID 25649350, PMID 25667295, PMID 26049686, PMID 26627641, PMID 26700304, PMID 28383633, PMID 28391775, PMID 29481630, PMID 29627309, PMID 30782413, PMID 31678771, PMID 32053771, PMID 33737338, PMID 35045358, PMID 37146227, PMID 37596461, PMID 38321811
2004 (1), 2025 (1), K23DE020197 (1)